Next Article in Journal
Anti-Salmonella Defence and Intestinal Homeostatic Maintenance In Vitro of a Consortium Containing Limosilactobacillus fermentum 3872 and Ligilactobacillus salivarius 7247 Strains in Human, Porcine, and Chicken Enterocytes
Previous Article in Journal
Searching for Antimicrobial-Producing Bacteria from Soils through an Educational Project and Their Evaluation as Potential Biocontrol Agents
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 13
Issue 1
10.3390/antibiotics13010031
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Phenotypic Detection of Carbapenemase and AmpC-β-Lactamase Production among Extended Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella spp. Isolated from Clinical Specimens

by
Zakaria Garba
1,2,*,
Bérenger Kaboré
2,
Isidore J. O. Bonkoungou
1,
Magloire H. Natama
2,
Toussaint Rouamba
2,
Kaisa Haukka
3,4,
Juha P. Kirveskari
5,
Halidou Tinto
2,
Lassana Sangaré
6,
Nicolas Barro
1 and
Anu Kantele
4,7,*
1
Department of Biochemistry and Microbiology, Université Joseph KI-ZERBO, Ouagadougou 03 BP 7021, Burkina Faso
2
Clinical Research Unit of Nanoro, Institut de Recherche en Sciences de la Santé, Ouagadougou 11 BP 218, Burkina Faso
3
Department of Microbiology, University of Helsinki, 00014 Helsinki, Finland
4
Human Microbiome Research Program, Medical Faculty, University of Helsinki, 00014 Helsinki, Finland
5
Helsinki Innovation Services Ltd., University of Helsinki, 00014 Helsinki, Finland
6
Department of Health Sciences, Université Joseph KI-ZERBO, Ouagadougou 03 BP 7021, Burkina Faso
7
Meilahti Infectious Diseases and Vaccine Research Center MeiVac, Helsinki University Hospital, 00029 Helsinki, Finland
*
Authors to whom correspondence should be addressed.
Antibiotics 2024, 13(1), 31; https://doi.org/10.3390/antibiotics13010031
Submission received: 9 November 2023 / Revised: 18 December 2023 / Accepted: 21 December 2023 / Published: 28 December 2023
Versions Notes

Abstract

:
Introduction: Data on antimicrobial resistance (AMR) are sparse across numerous African countries, as microbiological analyses are not routinely conducted and surveillance data are not collected. Accordingly, clinical samples are not routinely tested for carbapenem-resistant bacteria and, therefore, the general understanding of their prevalence in the region remains limited. Methods: Between January 2020 and June 2022, we collected extended spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-PE) isolates from five hospitals in Burkina Faso. After an initial culture on ESBL-selective media, the species were identified using API20E and isolates were tested against 13 antimicrobial agents using the disc diffusion method on Mueller–Hinton (MH) agar. ESBL production was confirmed via a double-disc synergy test. Production of carbapenemases and AmpC-β-lactamases and phenotypic co-resistance were determined. Results: Among the 473 ESBL-PE, 356 were ESBL-E. coli (ESBL-Ec) and 117 were Klebsiella spp. (ESBL-K). Of these isolates, 5.3% were carbapenemase and 5.3% were AmpC-β-lactamase-positive. Three types of carbapenemases were identified: 19 NDM, 3 OXA-48-like and 1 VIM. Two isolates produced both NDM and OXA-48-like carbapenemases. Carbapenemase producers were detected at all levels of healthcare. Co-resistance rates were up to 85% for aminoglycosides, 90% for sulfonamides, 95% for fluoroquinolones and 25% for chloramphenicol. Fosfomycin resistance was 6% for ESBL-Ec and 49% for ESBL-K (49%). Conclusions: Some of the ESBL-Ec and ESBL-K co-produced carbapenemases and/or AmpC-β-lactamases at all healthcare levels and in various sample types with high co-resistance rates to non-betalactams. Carbapenem resistance is no longer rare, calling for testing in routine diagnostics, a comprehensive resistance surveillance system and infection control within healthcare.

1. Introduction

The emergence and spread of multidrug-resistant (MDR) bacteria are serious global public health threats. In 2019, an estimated number of 4.95 million deaths were associated with antimicrobial resistance (AMR), with 1.27 million directly attributable to MDR bacteria [1]. The highest burden is in Western sub-Saharan Africa, with 27.3/100,000 AMR-attributable and 114.8/100,000 AMR-associated deaths [1]; the same region where AMR surveillance is minimal and resistance data are limited. The healthcare costs of AMR reach nearly USD 1.2 trillion in the “High-AMR” case [2]. According to the World Bank estimation/projection, by 2030, there will be an annual increase of USD 0.22 trillion in the extra health expenditure incurring in low-AMR settings [2].
Carbapenem resistance among Enterobacterales has experienced a dramatic increase and global spread over the past decade, with reports both from hospital and community settings [3]. The emergence of carbapenem resistance substantially limits the therapeutic options at hospitals worldwide since carbapenems are last-resort antibiotics [3,4], and, in accordance, infections due to carbapenem-resistant Enterobacterales (CRE) are associated with increased mortality rates [5,6,7]. Management of patients with CRE infections often requires combination therapy, which involves various types of antibiotics, such as tigecycline and colistin [8,9]. Microbiological analyses are a prerequisite for accurate treatment of patients with CRE infections. However, in low- and middle-income countries (LMICs), resistance data are scarce due to the challenges in detecting carbapenemases in microbiology laboratories [10,11]. Special attention should also be paid to ESBL-producing bacteria, which co-produce carbapenemases and/or AmpC, since carbapenem antibiotic agents are ineffective against them [12].
Two primary mechanisms account for carbapenem resistance among Enterobacterales: the first mechanism involves a reduction in membrane permeability by porin loss, often associated with the production of ESBL or AmpC-β-lactamase. The second mechanism entails the production of carbapenemase enzymes capable of hydrolyzing carbapenems [13]. However, although carbapenemase and AmpC-β-lactamase production is not routinely identified in clinical microbiology laboratories in LMICs, several recent studies across African hospitals have reported carbapenemase production among Enterobacterales [14,15,16,17,18,19,20]. Carbapenem resistance at rates of approximately 45% has been reported among E. coli and Klebsiella pneumoniae isolates from clinical specimens in two tertiary hospitals in Nigeria [15]. A phenotypic resistance rate of 23.3% and a genotypic resistance rate of 43.1% to carbapenem were reported in Uganda [17]. Data on AmpC-β-lactamase from Africa are also accumulating gradually. In a recent study, a high rate of AmpC-β-lactamase was reported in five referral hospitals in Khartoum, with the highest rates (49.3%) among Acinetobacter baumannii [21].
In Burkina Faso, data on the prevalence of CRE or AmpC-β-lactamase production among clinical isolates are limited. One study conducted in a referral teaching hospital identified 17 carbapenemase-producing strains, 4 in clinical samples and 13 in fecal carriage isolates from 443 Gram-negative bacteria [19]. Another study reported NDM genes in clinical E. coli isolates [22]. Recent studies in the country have discovered that carbapenemase-producing bacteria or their related genes are prevalent in the hospital waste water, implying their likely presence in clinical samples as well [23,24]. In the current study, we assessed the prevalence of carbapenemase and AmpC-β-lactamase production among ESBL-producing E. coli (ESBL-Ec) and ESBL-producing Klebsiella spp. (ESBL-K) isolated from clinical samples and their co-resistance to non-betalactam antibiotics and distribution in primary, secondary and tertiary healthcare institutions in Burkina Faso.

2. Results

2.1. Bacterial Strains

A total of 473 clinical ESBL-PE isolates, comprising 356 ESBL-Ec and 117 ESBL-K, were collected from inpatients and outpatients at the five hospitals participating in the study: CHU-YO: (Centre Hospitalier Universitaire Yalgado Ouedraogo), CHR-KDG (Reginal Hospital of Koudougou), El Fateh Suka medical clinic, CMA Source de vie and CMA Saint Camille de Nanoro (Table 1).

2.2. Prevalence of Carbapenemase-Producing Enterobacterales

In this study, the prevalence of carbapenemase production among the 473 ESBL-PE isolates was 5.3%. The 30 meropenem-resistant isolates were tested for carbapenemase production; 25 of them, 19 (76%) E. coli and 6 (24%) Klebsiella spp., were found to produce carbapenemases (Table 1). Carbapenemase-producing isolates were identified across all the three levels of the healthcare system. The frequency was the highest among ESBL-PE isolates collected at the tertiary hospitals, with a prevalence as high as 7.5% (22/293), yet the differences did not reach statistical significance. Regarding the distribution of carbapenemase-producing isolates by sample type, the rates appeared highest in urine samples with a prevalence of 6.7% (20/299 ESBL-PE), but again, the difference was not statistically significant (Table 1). The rates among ESBL-Ec and -K were similar (5.3% and 5.2%, respectively) (Table 1).

2.3. Types of Carbapenemase Produced

Among the carbapenamase-producing isolates, three types of carbapenemases were detected, with NDM (19/25; 76%) as the most frequent type, followed by OXA-48-like (3/25; 12%) and VIM (1/25; 4%). Two ESBL-Ec isolates were found to produce both NDM and OXA-48-like (2/25) carbapenemases. The rates of NDM were similar among ESBL-Ec (3.9%) and ESBL-K (4.3%) isolates (Table 2).

2.4. Prevalence and Distribution of AmpC-β-Lactamase Production

Among the 92 presumptive AmpC-β-lactamase-producing bacterial isolates (73 ESBL-Ec and 19 ESBL-K), 25 isolates (17 ESBL-Ec and 8 ESBL-K) tested positive. The prevalence of AmpC-β-lactamase production among the ESBL-producing isolates was 5.3% (25/473), 6.8% among ESBL-K isolates and 4.8% among ESBL-Ec isolates. The prevalence of AmpC-β-lactamase-producing isolates varied from 4.7 to less than 10% in all sample types (4.7% of ESBL-PE isolates in urine samples, 5.6% in pus and 9.7% in blood cultures). The frequency among ESBL-PE in the CHU-YO hospital was 6.5% (19/293) (Table 3).

2.5. Antimicrobial Resistance Patterns

As the study explored ESBL-PE, the strains are, by definition, resistant to most penicillin and cephalosporins. We explored the sensitivity to piperacillin + tazobactam and found 68% of ESBL-Ec and 77% ESBL-K as resistant.
As for carbapenem resistance, which was evaluated with disc diffusion test, approximately 6% of all isolates displayed resistance to imipenem and meropenem and up to 19% of ESBL-Ec and 13% of ESBL-K to ertapenem.
The resistance rates proved high also regarding fluoroquinolones (94%) and SXT (90%) (Table 4).
In the aminoglycoside family, isolates showed high resistance rates to kanamycin (approximately 86%) and tobramycin (approximately 60%). The lowest resistance rates were recorded for amikacin: 18% among ESBL-Ec and 9% among ESBL-K isolates.
Less than 25% of all isolates were resistant to chloramphenicol. A total of 6% of ESBL-Ec and 49% of ESBL-K isolates were resistant to fosfomycin (Table 4).

3. Discussion

Carbapenemase and AmpC-β-lactamase detection is not routine practice in microbiology laboratories in Africa, despite several studies reporting the presence of carbapenemase- and AmpC-β-lactamase-producing Enterobacterales [15,21,25,26,27,28,29,30]. In our study, the prevalence of carbapenemase production was 5.3%. Twenty-five isolates, primarily E. coli (76%), were carbapenemase producers, most of them originating in urine samples. Our results fall within the prevalence range of 2.6–6.7% reported in North Africa, but remain somewhat lower than the range of 9.0–60.0% reported in sub-Saharan Africa in a review from 2015 [31]. In our own country, Burkina Faso, a study conducted at Sanou Sourou teaching hospital in Bobo-Dioulasso reported a much lower prevalence than the present study; they only reported rates of 0.9% for carbapenemase producers among Gram-negative bacteria in clinical specimens, most of them urine samples [19]. Another study from Burkina Faso, consistent with our study, reported NDM, VIM, OXA-48 and KPC genes among E. coli isolates from clinical patient samples [22]. In contrast, a study conducted in a nearby region in northwestern Nigeria described much higher carbapenemase rates than in our study: two tertiary hospitals reported a prevalence of 39% among 248 ESBL and non-ESBL E. coli and Klebsiella pneumoniae clinical isolates. These isolates were primarily obtained from urine samples [15]. These variations in prevalence could be attributed to several factors, including differences in sample types, methods employed for carbapenemase detection, and the geographical regions in which the study was conducted. Nonetheless, in all the studies, carbapenemase-producing isolates were predominantly urinary pathogens. This can be attributed to two evident reasons: first, urine samples are among the most common samples investigated in microbiological laboratories, and second, urinary tract infections constitute the most prevalent symptomatic manifestation of intestinal colonization by MDR bacteria.
Both class B (NDM and VIM) and class D (OXA-48-like) carbapenemases were detected in our study. NDM carbapenemase-producing Enterobacterales were the most frequent findings (76%), consistent with results of several earlier studies from sub-Saharan Africa [17,22,31,32]. In our study, we identified carbapenemase-producing isolates in three hospitals, each representing different levels of the healthcare system. CHU-YO, a referral hospital at the highest level of specialized care facilities, showed a substantial prevalence of both. This may be attributed to the more abundant use of antibiotics, the use of broader spectrum antibiotics or the prolonged duration of drug treatments, as patients are referred from medical centers, regional hospitals or medical clinics where they have already received antimicrobial treatment. Indeed, the misuse or overuse of antibiotics during hospitalization can contribute to the selection of MDR bacteria [33,34].
Production of AmpC-β-lactamases was approximately 5% among our ESBL-E. coli and approximately 7% among our ESBL-Klebsiella isolates. Production of AmpC-β-lactamases has been described for Enterobacterales in general in some studies in Africa at various rates [21,30], for example, at a rate of 49.3% in Sudan [21], 15.2% in Nigeria [30], 2.5% in Ethiopia [25] and 36.5% in Uganda [35]. Co-production of ESBL- and AmpC-β-lactamase at a rate of 5.2% was observed in a previous study in India [27]. In a study in Ethiopia, 3.6% of AmpC-β-lactamase-positive isolates co-produced ESBL (5/139) [25]. All these data unmistakably confirm the presence of AmpC-β-lactamase in clinical isolates. Consequently, AmpC-β-lactamase detection should also be implemented in the routines of hospitals in Africa. This is of utmost importance since AmpC-β-lactamase production in bacteria can lead to challenges and failures of treatment, with increased morbidity and mortality [30].
A total of 473 ESBL-isolates (356 E. coli and 117 Klebsiella spp.) were tested against various antibiotics. Although the resistance rates to piperacillin + tazobactam remained high, carbapenem resistance was still low.
ESBL-producing Enterobacterales have been investigated in numerous studies in Africa, also revealing high resistance rates to betalactamase inhibitors [18,21,36,37]. Among our ESBL-producing isolates, resistance rates to piperacillin + tazobactam appeared even higher than in many other studies; for example, in 2017–2020 in Ghana, 49% of E. coli and 58% of Klebsiella sp. in urinary samples were resistant to piperacillin + tazobactam [36], compared to 68% and 77% in our clinical samples, respectively. A recent study in Ethiopia reported much lower resistance rates (12%) to piperacillin + tazobactam among ESBL and AmpC-betalactamase-producing Enterobacterales [25]. The high ESBL-PE rates in LMICs and their potential co-resistance should draw the attention of clinicians who often prescribe β-lactams in prophylaxis or infection management in healthcare facilities [38].
Although carbapenem-producing Enterobacterales often carry both ESBL and carbapenemase genes, not all CPE strains can be covered by a study on ESBL-PE, such as the present one. However, as most of the CPE strains are, it was of interest to see in Burkina Faso what proportion of ESBL-PE are actually CPE strains. Most (76%) of the identified CPE were E. coli, with NDM as the most common carbapenemase type, reaching a prevalence of approximately 4% among our ESBL-PE. The respective resistance rates measured with the disc diffusion method proved somewhat higher, reaching almost 20% for ertapenem among ESBL-Ec. Similar findings were reported in previous studies across Africa; resistance rates of 0 to 14.7% to imipenem and meropenem have been reported in recent studies in Togo, Nigeria, Ethiopia and Sudan among ESBL or AmpC-β-lactamase-producing isolates [21,25,39,40]. Our results were lower compared to the 58.6% resistance against imipenem reported in India, where antibiotic consumption is higher than in Burkina Faso [41] where their use is more controlled and the drugs are very expensive. Earlier studies in Burkina Faso have reported the presence of carbapenem-resistant strains both in feces and clinical isolates [19], while in a study in Ghana [42], all ESBL isolates were susceptible to meropenem. In Burkina Faso, the presence of resistance to carbapenem could be attributed to the co-presence of genetic determinants of resistance to carbapenems with those of other antibiotics commonly used in our hospitals [23].
Among our ESBL-PE isolates, co-resistance was recorded particularly against aminoglycosides, fluoroquinolones and sulfonamides. Among aminoglycosides, high resistance rates were recorded against all regimen tested, except amikacin. This finding is in line with those reported in similar studies in Burkina Faso [19], Togo [40], Sudan [21], Ethiopia [25], Algeria [18] and India [29,43]. Interestingly, our resistance rates appear high with respect to similar studies, which show wide variations in resistance level [39,44]. Our high rates could be associated with misuse or overuse of antibiotics in hospitals, communities or farms since these antibiotics are routinely used and are easy accessed [42].
This study had several limitations. Firstly, despite collecting samples from several laboratories, it would have benefitted from a higher sample size. Secondly, this study relied on phenotypic methods. These methods primarily detect enzyme production (ESBL, AmpC-betalactamase and carbapenemases), offering information on gene activity. Genotypic detection of genes encoding these phenotypes could have revealed even higher prevalence rates. In practice, however, phenotypic methods are more feasible for hospitals in resource-limited countries and should be integrated into routine activities of microbiology laboratories across West African countries.
Amikacin, fosfomycin and chloramphenicol emerged as the most effective antibiotics in vitro. Our results align with previous research in Burkina Faso in 2021 [19], Algeria in 2019 [18], and Nigeria in 2014 [39], yet contrast the higher resistance to amikacin observed in Ghana in 2013 [44]. Apart from fosfomycin being one of the alternative drugs for cystitis (IDSA guideline), these three antibiotics are initially not preferred for many infections but rather represent reserve antibiotics in current practice. Indeed, when treating infections caused by ESBL- or carbapenemase-producing Enterobacterales, it is often necessary to resort to less effective reserve antibiotics.

4. Material and Methods

4.1. Study Design and Period

The prospective study was carried out in five hospitals in Burkina Faso from January 2020 to June 2022. ESBL-producing E. coli and Klebsiella spp. strains isolated from urine, blood and pus samples were collected from each hospital over a 12-month period. All isolates were characterized in the CRUN microbiology laboratory.

4.2. Sampling and Site Description

Burkina Faso is a West African country with a population estimated at 22,489,126 [45] and a GPT of USD 2682 per capita [46]. The health system in Burkina Faso comprises three levels. The first level encompasses peripheral healthcare facilities and primary hospitals. The second level comprises regional hospitals and certain medical clinics, which serve as reference facilities for primary hospitals. The third level includes national and teaching hospitals, representing the highest level of referral care and offering specialized services [47]. Routine practices do not cover microbiological analyses of resistant bacteria; microbiological laboratories are scarce and analyses with cultures and resistance profiles are not routinely conducted in the country.
Sampling was carried out in five hospitals, each selected to represent different levels of the health system: (1) Yalgado Ouédraogo teaching hospital (CHU-YO), a tertiary hospital located in the capital city, Ouagadougou; (2) the regional hospital of Koudougou (CHR-KDG) and (3) the El Fateh Suka medical clinic in Ouagadougou, both categorized as secondary hospitals; and two medical centers representing primary healthcare, (4) CMA Saint Camille de Nanoro, a rural medical center, and (5) CMA évangélique Source de vie in Ouagadougou. This diverse selection of healthcare units allowed a comprehensive sampling approach. A total of 473 clinical isolates were collected, comprising 356 ESBL-Ec and 117 ESBL-K strains. These isolates were collected from various clinical specimens, including urine (N = 303), pus (N = 140) and blood cultures (N = 30). The isolates were collected in tryptic soy agar tubes and kept at room temperature until transferal to the Clinical Research Unit of Nanoro (CRUN) microbiology laboratory for analysis.

4.3. Bacterial Isolation and Species Identification

At the CRUN microbiology lab, isolates from the tryptic soy agar tubes were plated on ESBL-selective chromogenic culture media (CHROMagarTM ESBL, Paris, France). All isolates were subjected to species identification of the isolates by API 20E (Biomérieux, Marcy-l’étoile, France) according to the manufacturer’s instructions.

4.4. ESBL Production Test

All isolates identified were tested for ESBL production using the double disc synergy test between 3rd generation cephalosporins (ceftriaxone and ceftazidime) and 4th generation cephalosporin (cefepime) discs and amoxicillin-clavulanic acid discs according to the American Clinical and Laboratory Standards Institute (CLSI) 2022 guidelines. ESBL production was indicated by the presence of a synergistic inhibition zone between ceftazidime, ceftriaxone and/or cefepime and the amoxicillin-clavulanic acid disc.

4.5. Carbapenemase Production Test

Isolates were screened to select meropenem resistance for a carbapenemases production test according to the CLSI 2022 guidelines. A total of 30 isolates (22 E. coli and 8 Klebsiella spp.) that had a meropenem inhibition zone diameter less than 22 mm in the antimicrobial susceptibility test (AST) were investigated for production of the five main carbapenemases (OXA48-like, NDM, KPC, VIM and IMP) using an immunochromatographic test O.K.N.V.I. RESIST-5 (CORIS BioConcept, Gembloux, Belgium), according to the manufacturer’s instructions.

4.6. AmpC-β-Lactamase Production

Bacterial isolates with a cefoxitin inhibition zone diameter less than 18 mm (≤18 mm) were presumed as AmpC-β-lactamase producers. A total of 92 presumptive AmpC-β-lactamase producers’ bacterial isolates (73 ESBL-E. coli and 19 ESBL-Klebsiella spp.) were tested for AmpC-β-lactamase production using MH agar supplemented with cloxacillin at 4 µg/L. A bacterial suspension prepared with fresh colonies (McFarland 0.5) was inoculated on to the entire surface of the MH agar supplemented with cloxacillin at 4 µg/L and a disc of cefoxitin was placed on the plate. The test was positive if the inhibition zone diameter around the cefoxitin disc was ≥18 mm.

4.7. Antimicrobial Susceptibility Testing

An antimicrobial susceptibility test (AST) was performed using the disc diffusion method on Mueller–Hinton (MH) agar as described by Bauer et al. [48]. In total, 473 ESBL-producing isolates (356 E. coli and 117 Klebsiella spp.) were tested. The results were interpreted according to the American Clinical and Laboratory Standards Institute (CLSI) 2022 guidelines. A total of 13 antibiotics were tested, as listed in Table 4.

4.8. Statistical Analysis

The proportions were compared using Pearson’s Chi-square test or Fisher’s exact test as applicable.

5. Conclusions

Our study in Burkina Faso revealed that approximately 5% of ESBL-producing E. coli and Klebsiella spp. isolates produced carbapenemases and/or AmpC-βlactamases. These highly resistant pathogens were found at all levels of healthcare. Three types of carbapenemases, NDM, OXA-48-like and VIM, were detected, with NDM as the most prevalent. The antibiotic resistance patterns revealed notable co-resistance to antibiotics commonly used for patient treatment. Implementing antibiotic stewardship in all levels of healthcare and establishing effective and reliable AMR surveillance systems are essential measures for containing resistant bacteria and preventing their dissemination within hospitals and into the broader communities.

Author Contributions

Conceptualization, Z.G., I.J.O.B., M.H.N., K.H., L.S., N.B. and A.K.; Formal analysis, B.K., T.R. and J.P.K.; Writing—original draft, Z.G., B.K., I.J.O.B., J.P.K., L.S. and N.B.; Writing—review and editing, K.H. and A.K.; Project administration, H.T.; Funding acquisition, K.H., H.T. and A.K. All authors have read and agreed to the published version of the manuscript.

Funding

The study was supported by the Belgium Directorate General for Development Cooperation (DGD) through the collaborative framework agreement 4 (FA4–DGD program) between Clinical Research Unit of Nanoro (CRUN), Burkina Faso, and the Institute of Tropical Medicine of Antwerp (ITM), Belgium, and the Academy of Finland through the AMRIWA project (grant 318642). The Open access fee was provided by Finnish institutions (FinELib).

Institutional Review Board Statement

This study is part of the AMRIWA project which received approval from the health research committee of Burkina Faso (N° 153-12-2018/ CERS). In addition, authorizations were obtained from each hospital’s directing staff.

Data Availability Statement

Data are contained within the article.

Acknowledgments

We sincerely thank the microbiology laboratory staff of the participating hospitals for their assistance in sampling. We also thank the staff of the clinical biology laboratory of CRUN, who helped us enormously with sample analysis.

Conflicts of Interest

Helsinki Innovation Services Ltd is a technology transfer company of Helsinki University, not a commercial company in its usual meaning. The idea is to evaluate the commercial significance of research-born ideas and inventions at the University and help researchers with matters such as finding funding for the preparation of commercialization, out-licensing of technologies, IPR, and establishing spinout companies.

References

  1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022, 399, 629–655, Erratum in Lancet 2022, 400, 1102. [Google Scholar] [CrossRef]
  2. World Bank. Drug-Resistant Infections: A Threat to Our Economic Future; World Bank: Washington, DC, USA, 2017. [Google Scholar]
  3. Centers for Disease Control and Prevention (CDC). Vital Signs: Carbapenem-resistant Enterobacteriaceae. MMWR Morb. Mortal. Wkly. Rep. 2013, 62, 165–170. [Google Scholar]
  4. Armstrong, T.; Fenn, S.J.; Hardie, K.R. JMM Profile: Carbapenems: A broad-spectrum antibiotic. J. Med. Microbiol. 2021, 70, 001462. [Google Scholar] [CrossRef]
  5. Zhou, R.; Fang, X.; Zhang, J.; Zheng, X.; Shangguan, S.; Chen, S.; Shen, Y.; Liu, Z.; Li, J.; Zhang, R.; et al. Impact of carbapenem resistance on mortality in patients infected with Enterobacteriaceae: A systematic review and meta-analysis. BMJ Open 2021, 11, e054971. [Google Scholar] [CrossRef]
  6. Hu, Q.; Chen, J.; Sun, S.; Deng, S. Mortality-related risk factors and novel antimicrobial regimens for carbapenem-resistant Enterobacteriaceae infections: A systematic review. Infect. Drug Resist. 2022, 15, 6907–6926. [Google Scholar] [CrossRef]
  7. Garbati, M.A.; Sakkijha, H.; Abushaheen, A. Infections due to carbapenem resistant Enterobacteriaceae among Saudi Arabian hospitalized patients: A matched case-control study. BioMed Res. Int. 2016, 2016, 3961684. [Google Scholar] [CrossRef]
  8. Tompkins, K.; van Duin, D. Treatment for carbapenem-resistant Enterobacterales infections: Recent advances and future directions. Eur. J. Clin. Microbiol. Infect. Dis. 2021, 40, 2053–2068. [Google Scholar] [CrossRef]
  9. Iovleva, A.; Doi, Y. Carbapenem-resistant Enterobacteriaceae. Clin. Lab. Med. 2017, 37, 303–315. [Google Scholar] [CrossRef]
  10. Hirsch, E.B.; Tam, V.H. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): An emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother. 2010, 65, 1119–1125. [Google Scholar] [CrossRef]
  11. Iskandar, K.; Molinier, L.; Hallit, S.; Sartelli, M.; Hardcastle, T.C.; Haque, M.; Lugova, H.; Dhingra, S.; Sharma, P.; Islam, S.; et al. Surveillance of antimicrobial resistance in low- and middle-income countries: A scattered picture. Antimicrob. Resist. Infect. Control 2021, 10, 63. [Google Scholar] [CrossRef]
  12. Rodriguez-Baño, J.; Gutiérrez-Gutiérrez, B.; Machuca, I.; Pascual, A. Treatment of Infections Caused by Extended-Spectrum-Beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin. Microbiol. Rev. 2018, 31, 1–42. [Google Scholar] [CrossRef]
  13. Logan, L.K.; Weinstein, R.A. The epidemiology of carbapenem-resistant enterobacteriaceae: The impact and evolution of a global menace. J. Infect. Dis. 2017, 215 (Suppl. S1), S28–S36. [Google Scholar] [CrossRef]
  14. Yehouenou, C.L.; Soleimani, R.; Kpangon, A.A.; Simon, A.; Dossou, F.M.; Dalleur, O. Carbapenem-resistant organisms isolated in surgical site infections in Benin: A public health problem. Trop. Med. Infect. Dis. 2022, 7, 200. [Google Scholar] [CrossRef]
  15. Ibrahim, Y.; Sani, Y.; Saleh, Q.; Saleh, A.; Hakeem, G. Phenotypic detection of extended spectrum beta lactamase and carbapenemase co-producing clinical isolates from two tertiary hospitals in Kano, north west Nigeria. Ethiop. J. Health Sci. 2017, 27, 3–10. [Google Scholar] [CrossRef]
  16. Walkty, A.; Gilmour, M.; Simner, P.; Embil, J.M.; Boyd, D.; Mulvey, M.; Karlowsky, J. Isolation of multiple carbapenemase-producing Gram-negative bacilli from a patient recently hospitalized in Nigeria. Diagn. Microbiol. Infect. Dis. 2015, 81, 296–298. [Google Scholar] [CrossRef]
  17. Ssekatawa, K.; Byarugaba, D.K.; Nakavuma, J.L.; Kato, C.D.; Ejobi, F.; Tweyongyere, R.; Eddie, W.M. Prevalence of pathogenic Klebsiella pneumoniae based on PCR capsular typing harbouring carbapenemases encoding genes in Uganda tertiary hospitalsmodee. Antimicrob. Resist. Infect. Control 2021, 10, 1–10. [Google Scholar] [CrossRef]
  18. Nabti, L.Z.; Sahli, F.; Radji, N.; Mezaghcha, W.; Semara, L.; Aberkane, S.; Lounnas, M.; Solassol, J.; Didelot, M.-N.; Jean-Pierre, H.; et al. High prevalence of multidrug-resistant Escherichia coli in urine samples from inpatients and outpatients at a tertiary care hospital in sétif, Algeria. Microb. Drug Resist. 2019, 25, 386–393. [Google Scholar] [CrossRef]
  19. Sanou, S.; Ouedraogo, A.S.; Aberkane, S.; Vendrell, J.; Ouchar, O.; Bouzimbi, N.; Hema, A.; Poda, A.; Zoungrana, J.; Ouedraogo, G.A.; et al. Prevalence and molecular characterization of extended spectrum β-Lactamase, plasmid-mediated quinolone resistance, and carbapenemase-producing Gram-negative bacilli in Burkina Faso. Microb. Drug Resist. 2021, 27, 18–24. [Google Scholar] [CrossRef]
  20. Ballot, D.E.; Bandini, R.; Nana, T.; Bosman, N.; Thomas, T.; Davies, V.A.; Cooper, P.A.; Mer, M.; Lipman, J. A review of -multidrug-resistant Enterobacteriaceae in a neonatal unit in Johannesburg, South Africa. BMC Pediatr. 2019, 19, 320. [Google Scholar] [CrossRef]
  21. Dirar, M.; Bilal, N.; Ibrahim, M.E.; Hamid, M. Resistance patterns and phenotypic detection of β-lactamase enzymes among Enterobacteriaceae isolates from referral hospitals in Khartoum State, Sudan. Cureus 2020, 12, e7260. [Google Scholar] [CrossRef]
  22. Kaboré, B.; Ouédraogo, H.S.; Zongo, O.; Ouédraogo, G.A.; Tapsoba, F.; Bougma, S.; Zongo, K.J.; Zeba, B.; Traoré, Y.; Sanou, I.; et al. Emergence of New Delhi metallo- β -Lactamase (NDM) genes detected from clinical strains of Escherichia coli isolated in Ouagadougou, Burkina Faso. Int. J. Microbiol. 2023, 2023, 4813225. [Google Scholar] [CrossRef]
  23. Markkanen, M.A.; Haukka, K.; Pärnänen, K.M.M.; Dougnon, V.T.; Bonkoungou, I.J.O.; Garba, Z.; Tinto, H.; Sarekoski, A.; Karkman, A.; Kantele, A.; et al. Metagenomic analysis of the abundance and composition of antibiotic resistance genes in hospital wastewater in Benin, Burkina Faso, and Finland. mSphere 2023, 8, e0053822. [Google Scholar] [CrossRef]
  24. Kagambèga, A.B.; Dembélé, R.; Bientz, L.; M’Zali, F.; Mayonnove, L.; Mohamed, A.H.; Coulibaly, H.; Barro, N.; Dubois, V. Detection and characterization of carbapenemase-producing detection and characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae from Hospital effluents of Ouagadougou, Burkina Faso. Antibiotics 2023, 12, 1494. [Google Scholar] [CrossRef]
  25. Tekele, S.G.; Teklu, D.S.; Tullu, K.D.; Birru, S.K.; Legese, M.H. Extended-spectrum beta-lactamase and AmpC beta-lactamases producing gram negative bacilli isolated from clinical specimens at international clinical laboratories, Addis Ababa, Ethiopia. PLoS ONE 2020, 15, e0241984. [Google Scholar] [CrossRef]
  26. Kazemian, H.; Heidari, H.; Ghanavati, R.; Ghafourian, S.; Yazdani, F.; Sadeghifard, N.; Valadbeigi, H.; Maleki, A.; Pakzad, I. Phenotypic and genotypic characterization of ESBL-, AmpC-, and carbapenemase-producing Klebsiella pneumoniae and Escherichia coli isolates. Med. Princ. Pract. 2019, 28, 547–551. [Google Scholar] [CrossRef]
  27. Salvia, T.; Dolma, K.G.; Dhakal, O.P.; Khandelwal, B.; Singh, L.S. Phenotypic Detection of ESBL, AmpC, MBL, and Their Co-occurrence among MDR Enterobacteriaceae Isolates. J. Lab. Physicians 2022, 14, 329–335. [Google Scholar] [CrossRef]
  28. Khalifa, S.M.; Abd El-Aziz, A.M.; Hassan, R.; Abdelmegeed, E.S. β-lactam resistance associated with β-lactamase production and porin alteration in clinical isolates of E. coli and K. pneumoniae. PLoS ONE 2021, 16, e0251594. [Google Scholar] [CrossRef]
  29. Rubee Chanu, T.; Shah, P.K.; Soni, S.; Ghosh, A. Phenotypic detection of extended spectrum, AmpC, metallo beta-lactamases and their coexistence in clinical isolates of commonly isolated gram negativebacteria in GKGH hospital, Bhuj. IP Int. J. Med. Microbiol. Trop. Dis. 2019, 5, 52–56. [Google Scholar] [CrossRef]
  30. Ogefere, H.O.; Osikobia, J.G.; Omoregie, R. Prevalence of AmpC β-lactamase among Gram-negative bacteria recovered from clinical specimens in Benin City, Nigeria. Trop. J. Pharm. Res. 2016, 15, 1947–1953. [Google Scholar] [CrossRef]
  31. Manenzhe, R.I.; Zar, H.J.; Nicol, M.P.; Kaba, M. The spread of carbapenemase-producing bacteria in Africa: A systematic review. J. Antimicrob. Chemother. 2015, 70, 23–40. [Google Scholar] [CrossRef]
  32. Awoke, T.; Teka, B.; Aseffa, A.; Sebre, S.; Seman, A.; Yeshitela, B.; Abebe, T.; Mihret, A. Detection of blaKPC and blaNDM carbapenemase genes among Klebsiella pneumoniae isolates in Addis Ababa, Ethiopia: Dominance of blaNDM. PLoS ONE 2022, 17, e0267657. [Google Scholar] [CrossRef]
  33. Ouedraogo, A.S.; Jean-Pierre, H.; Banuls, A.L.; Ouedraogo, R.G.S. Émergence et diffusion de la résistance aux antibiotiques en Afrique de l’Ouest: Facteurs favorisants et évaluation de la menace. Med. Sante Trop. 2017, 27, 147–154. [Google Scholar]
  34. Michael, C.A.; Dominey-Howes, D.; Labbate, M. The antimicrobial resistance crisis: Causes, consequences, and management. Front. Public Health 2014, 2, 145. [Google Scholar] [CrossRef]
  35. Nakaye, M.; Bwanga, F.; Itabangi, H.; Stanley, I.J.; Bashir, M.; Bazira, J. AmpC-BETA Lactamases among Enterobacteriaceae isolated at a tertiary hospital, south western Uganda. Br. Biotechnol. J. 2014, 4, 1026–1036. [Google Scholar] [CrossRef]
  36. Asamoah, B.; Labi, A.K.; Gupte, H.A.; Davtyan, H.; Peprah, G.M.; Adu-Gyan, F.; Nair, D.; Muradyan, K.; Jessani, N.S.; Sekyere-Nyantakyi, P. High Resistance to Antibiotics Recommended in Standard Treatment Guidelines in Ghana: A Cross-Sectional Study of Antimicrobial Resistance Patterns in Patients with Urinary Tract Infections between 2017–2021. Int. J. Environ. Res. Public Health 2022, 19, 6556. [Google Scholar] [CrossRef]
  37. Silago, V.; Moremi, N.; Mtebe, M.; Komba, E.; Masoud, S.; Mgaya, F.X.; Mirambo, M.M.; Nyawale, H.A.; Mshana, S.E.; Matee, M.I. Multidrug-Resistant Uropathogens Causing Community Acquired Urinary Tract Infections among Patients Attending Health Facilities in Mwanza and Dar es Salaam, Tanzania. Antibiotics 2022, 11, 1718. [Google Scholar] [CrossRef]
  38. Bhaskar, T.; Lahon, K. The betalactam antibiotics as an empirical therapy in a eeveloping country: An update on their current status and recommendations to counter the resistance against them. J. Clin. Diagn. Res. 2013, 7, 1207–1214. [Google Scholar] [CrossRef]
  39. Yusuf, I.; Arzai, A.H.; Haruna, M.; Sharif, A.A.; Getso, M.I. Detection of multi drug resistant bacteria in major hospitals in Kano, North-West, Nigeria. Braz. J. Microbiol. 2014, 45, 791–798. [Google Scholar] [CrossRef]
  40. Salah, F.D.; Diagbouga, S.; Dabire, A.M. First detection of resistance genes encoding extended spectrum beta-lactamase producing Escherichia coli at Lome, Togo. Arch. Clin. Microbiol. 2016, 7, 1–7. [Google Scholar] [CrossRef]
  41. Koya, S.F.; Ganesh, S.; Selvaraj, S.; Wirtz, V.J.; Galea, S.; Rockers, P.C. Antimicrobial resistance antibiotic consumption in India: Geographical variations and temporal changes between 2011 and 2019. JAC-Antimicrobial Resist. 2022, 4, dlac112. [Google Scholar] [CrossRef]
  42. Dadgostar, P. Antimicrobial resistance: Implications and costs. Infect. Drug Resist. 2019, 12, 3903–3910. [Google Scholar] [CrossRef] [PubMed]
  43. Khanna, D.A.; Khanna, D.M.; Sharma, D.S. Detection of various beta lactamases in gram negative bacteria and their resistance pattern in northern India. Trop. J. Pathol. Microbiol. 2016, 2, 70–75. [Google Scholar] [CrossRef]
  44. Obeng-Nkrumah, N.; Twum-Danso, K.; Krogfelt, K.A.; Newman, M.J. High levels of extended-spectrum beta-lactamases in a major teaching hospital in Ghana: The need for regular monitoring and evaluation of antibiotic resistance. Am. J. Trop. Med. Hyg. 2013, 89, 960–964. [Google Scholar] [CrossRef] [PubMed]
  45. Faso, F. The World Factbook; Central Intelligence Agency: Langley, VA, USA, 2023. [Google Scholar]
  46. International Monetary Fund. World Economic Outlook Database, October 2023 Edition. (BF). Available online: https://www.imf.org/en/Countries/BFA (accessed on 22 December 2023).
  47. Ministerie de la Santé, Burkina Faso. Annuaire Statistique. 2014. Available online: http://www.cns.bf/IMG/pdf/annuaire_2014_du_ms.pdf (accessed on 22 December 2023).
  48. Bauer, A.W.; Kirby, W.M.; Sherris, J.C.; Turck, M. Antibiotic susceptibility testing by a standardized single disk method. Am. J. Clin. Pathol. 1966, 45, 493–496. [Google Scholar] [CrossRef]
Table 1. Prevalence of carbapenemase-producing isolates among extended-spectrum betalactamase (ESBL)-producing Enterobacterales: data provided by hospitals and sample type.
Table 1. Prevalence of carbapenemase-producing isolates among extended-spectrum betalactamase (ESBL)-producing Enterobacterales: data provided by hospitals and sample type.
ESBL-
E. coli
N = 356
n/N (%)		ESBL-
Klebsiella spp.
N = 117
n/N (%)		All Isolates
N = 473
n/N (%)		Prevalence (%)p-Value
Hospitals 0.14 a
 CHU-YO18/211 (8.5) 4/82 (4.9)22/2937.5
 CHR-KDG1/44 (2.3)0/13 (0)1/571.8
 El Fateh Suka medical clinic0/24 (0)0/0 (0)0/240
 CMA Saint Camille de Nanoro0/58 (0)2/14 (1.4)2/742.7
 CMA évangélique source de vie0 /19 (0)0/8 (0)0/270
Sample Type 0.20 b
 Urine16/228 (7.0)4/71 (5.6)20/2996.7
 Pus 2/113 (1.8)2/30 (6.7)4/1432.8
 Blood culture1/15 (6.7)0/16 (0)1/313.2
Overall prevalence19/356 (5.3)6 /117(5.1)25/4735.3
N = number of isolates tested; n = number of resistant isolates; a Fisher’s exact test for count data for comparisons between healthcare settings. b Pearson’s Chi-squared test for comparisons between sample types.
Table 2. Carbapenemase findings among ESBL-PE isolates and proportions of each carbapenemase type.
Table 2. Carbapenemase findings among ESBL-PE isolates and proportions of each carbapenemase type.
ESBL-
E. coli
N = 356
n (%)		ESBL-
Klebsiella spp., N = 117
n (%)		All Isolates
N = 473
n (%)		Isolates with Carbapenemase N = 25
n (%)
Carbapenemases
 NDM14 (3.9)5 (4.3)19 (4.0)19/25 (76)
 OXA-48-like3 (0.8)0 (0)3 (0.6)3/25 (12)
 OXA-48-like + NDM2 (0.6)0 (0)2 (0.4)2/25 (8)
 VIM0 (0)1 (0.9)1 (0.2)1/25 (4)
Total19 (5.3)6 (5.1)25 (5.3)25 (100)
N = number of isolates tested; n = number of resistant isolates.
Table 3. Prevalence of AmpC-β-lactamase-producing isolates among ESBL-producing Enterobacterales; data provided by hospital and type of sample.
Table 3. Prevalence of AmpC-β-lactamase-producing isolates among ESBL-producing Enterobacterales; data provided by hospital and type of sample.
ESBL-
E. coli
N = 356
n/N (%)		ESBL-
Klebsiella spp.
N = 117
n/N (%)		All Isolates
N = 473
n/N (%)		Prevalence (%)p-Value
Hospitals 0.12 a
 CHU-YO13/211 (6.2) 6 /82 (7.3)19/2936.5
 CHR-KDG0/44 (0)0/13 (0)0/570
 El Fateh Suka medical clinic2 /24 (8.3)0/0 (0)2/248.3
 CMA Saint Camille de Nanoro1/58 (1.7)1/14 (7.1)2/742.7
 CMA évangélique Source de vie1/19 (5.3)1/8 (12.5)2/277.4
Sample Type 0.49 b
 Urines8/228 (3.5)6/71 (8.5)14/2994.7
 Pus7/113 (6.2)1/30 (3.3)8/1435.6
 Bloodculture2/15 (13.3)1/16 (6.3)3/319.7
Overall prevalence17/356 (4.8)8/117 (6.8)25/4735.3
N = number of isolates tested; n = number of resistant isolates; a Fisher’s exact test for count data for comparisons between healthcare settings. b Pearson’s Chi-squared test for comparisons between sample types.
Table 4. Resistance to various antibiotics among ESBL-producing E. coli and Klebsiella sp.; isolates tested via the disc diffusion method.
Table 4. Resistance to various antibiotics among ESBL-producing E. coli and Klebsiella sp.; isolates tested via the disc diffusion method.
Antibiotics (Concentration in µg)ESBL- E. coli
N = 356 		ESBL-Klebsiella spp.
N = 117
ResistanceResistance
n (%)n (%)
 Piperacillin + Tazobactam (110)242 (68.0)90 (76.9)
 Meropenem (10)22 (6.2)8 (6.8)
 Imipenem (10)21 (5.9)8 (6.8)
 Ertapenem (10)69 (19.4)15 (12.8)
 Gentamicin (10)153 (42.9)68 (58.1)
 Amikacin (30)65 (18.3)11 (9.4)
 Tobramycin (10)215 (60.4)69 (59.0)
 Kanamycin (30)303 (85.1)101 (86.3)
 Ciprofloxacin (5)335 (94.1)110 (94.0)
 Sulfamethoxazole + trimethoprim (25)297 (834)105 (89.7)
 Nitrofurantoin (300)118 (33.1)87 (74.4)
 Fosfomycin (200)20 (5.6)57 (48.7)
 Chloramphenicol71 (19.9)29 (24.8)
N = number of isolates tested; n = number of resistant isolates.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Garba, Z.; Kaboré, B.; Bonkoungou, I.J.O.; Natama, M.H.; Rouamba, T.; Haukka, K.; Kirveskari, J.P.; Tinto, H.; Sangaré, L.; Barro, N.; et al. Phenotypic Detection of Carbapenemase and AmpC-β-Lactamase Production among Extended Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella spp. Isolated from Clinical Specimens. Antibiotics 2024, 13, 31. https://doi.org/10.3390/antibiotics13010031

AMA Style

Garba Z, Kaboré B, Bonkoungou IJO, Natama MH, Rouamba T, Haukka K, Kirveskari JP, Tinto H, Sangaré L, Barro N, et al. Phenotypic Detection of Carbapenemase and AmpC-β-Lactamase Production among Extended Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella spp. Isolated from Clinical Specimens. Antibiotics. 2024; 13(1):31. https://doi.org/10.3390/antibiotics13010031

Chicago/Turabian Style

Garba, Zakaria, Bérenger Kaboré, Isidore J. O. Bonkoungou, Magloire H. Natama, Toussaint Rouamba, Kaisa Haukka, Juha P. Kirveskari, Halidou Tinto, Lassana Sangaré, Nicolas Barro, and et al. 2024. "Phenotypic Detection of Carbapenemase and AmpC-β-Lactamase Production among Extended Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella spp. Isolated from Clinical Specimens" Antibiotics 13, no. 1: 31. https://doi.org/10.3390/antibiotics13010031

APA Style

Garba, Z., Kaboré, B., Bonkoungou, I. J. O., Natama, M. H., Rouamba, T., Haukka, K., Kirveskari, J. P., Tinto, H., Sangaré, L., Barro, N., & Kantele, A. (2024). Phenotypic Detection of Carbapenemase and AmpC-β-Lactamase Production among Extended Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella spp. Isolated from Clinical Specimens. Antibiotics, 13(1), 31. https://doi.org/10.3390/antibiotics13010031

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop